Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Therapeutic prospects in autoimmunity]

J P Revillard1

  • 1Laboratoire d'immunologie, INSERM U 80, hôpital Edourd-Herriot, Lyon.

La Revue Du Praticien
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Ia antibodies in therapy.

Immunology today·2014
Same author

[Mechanisms of autoimmunity and therapeutic implications].

La Revue du praticien·2002
Same author

6-Methylprednisolone does not impair anti-thymocyte globulin (ATG) immunosuppressive activity in non-human primates.

Transplant immunology·2001
Same author

Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models.

Transplantation proceedings·2001
Same author

Immunosuppression in composite tissue allografts.

Transplantation proceedings·2001
Same author

Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model.

Transplantation·2001

New immunosuppressive therapies are emerging for autoimmune diseases, moving beyond traditional corticosteroids. These advanced treatments, including Cyclosporin A and monoclonal antibodies, offer novel therapeutic strategies currently under clinical evaluation.

Area of Science:

  • Immunology
  • Pharmacology

Context:

  • Autoimmune disease treatment historically relies on corticosteroids and general immunosuppressants.
  • Transplantation advancements have spurred the development of targeted immunosuppressive agents.

Purpose:

  • To review evolving therapeutic strategies for autoimmune diseases.
  • To highlight novel immunosuppressive agents and their evaluation methods.

Summary:

  • Cyclosporin A demonstrates efficacy in various autoimmune conditions.
  • Emerging treatments include intravenous immunoglobulins, cytokine/anticytokine therapies, immunotoxins, and monoclonal antibodies (targeting CD4, CD25, LFA-1).
  • Peptide vaccination represents a future therapeutic avenue.

Impact:

Related Experiment Videos

  • These advancements offer potential for more effective and targeted autoimmune disease management.
  • Clinical trials are crucial for validating the efficacy and safety of new immunosuppressive treatments.